Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Refining neoadjuvant immunotherapy for resectable lung cancer

In an era of expanding perioperative approaches for resectable non–small-cell lung cancer, new data demonstrate that dual neoadjuvant immunotherapy targeting PD-1 and LAG-3 is feasible; future analyses may enhance patient selection by identifying immune signatures predictive of response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Study design for NEOpredict-Lung.

References

  1. Sung, H. et al. CA Cancer J. Clin. 71, 209–249 (2021).

    Article  PubMed  Google Scholar 

  2. The National Lung Screening Trial Research Team. N. Engl. J. Med. 365, 395–409 (2011).

    Article  PubMed Central  Google Scholar 

  3. Pignon, J. P. et al. J. Clin. Oncol. 26, 3552–3559 (2008).

    Article  PubMed  Google Scholar 

  4. Desai, A. P., Adashek, J. J., Reuss, J. E., West, H. J. & Mansfield, A. S. JAMA Oncol. 9, 135–142 (2023).

    Article  PubMed  Google Scholar 

  5. Sorin, M. et al. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2024.0057 (2024).

  6. Schuler, M. Nat. Med. https://doi.org/10.1038/s41591-024-02965-0 (2024).

    Article  PubMed  Google Scholar 

  7. Wakelee, H. et al. N. Engl. J. Med. 389, 491–503 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Forde, P. M. et al. N. Engl. J. Med. 386, 1973–1985 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pellini, B. & Chaudhuri, A. A. J. Clin. Oncol. 40, 567–575 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mino-Kenudson, M. et al. J. Thorac. Oncol. 17, 1335–1354 (2022).

    Article  CAS  PubMed  Google Scholar 

  11. Skoulidis, F. et al. Cancer Discov. 8, 822–835 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Qiao, M. et al. J. Thorac. Oncol. 16, 1267–1288 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christine M. Lovly.

Ethics declarations

Competing interests

M.D.S. previously served on the speakers’ bureau for Jazz Pharmaceuticals and has served on advisory board for Jazz Pharmaceuticals and AstraZeneca. C.M.L. has served on advisory boards for Amgen, AnHeart, Arrivent, AstraZeneca, Blueprints Medicine, BMS, Boehringer Ingelheim, Cepheid, D2G, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech, Gilead, Guardant, Indupro, Janssen, Medscape, Novartis, Pfizer, Regeneron, Roche, Takeda and Tempus and has also served on a data and safety monitoring board for Janssen (uncompensated).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shields, M.D., Lovly, C.M. Refining neoadjuvant immunotherapy for resectable lung cancer. Nat Med 30, 1535–1536 (2024). https://doi.org/10.1038/s41591-024-03001-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-024-03001-x

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer